Valuation: Modalis Therapeutics Corporation

Market Cap 3.21B 20.15M 17.47M 16.38M 14.93M 28.1M 1.92B 28.55M 193M 75.28M 963M 75.67M 74.03M P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 400M 2.51M 2.18M 2.04M 1.86M 3.5M 240M 3.56M 24.01M 9.38M 120M 9.42M 9.22M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.09%
Yield 2024 *
-
Yield 2025 -
06-12 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
05-27 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
05-13 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-12 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/08/25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
07/08/25 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
07/07/25 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
16/06/25 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
09/06/25 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
01/05/25 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
27/01/25 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
06/01/25 JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease MT
06/01/25 Jcr Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation Announces Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy CI
1 day+6.45%
1 week+3.12%
Current month+10.00%
1 month-2.94%
3 months-51.47%
6 months-44.07%
Current year-41.07%
1 week 31
Extreme 31
33
1 month 29
Extreme 29
38
Current year 29
Extreme 29
83
1 year 29
Extreme 29
97
3 years 29
Extreme 29
203
5 years 29
Extreme 29
1,667
10 years 29
Extreme 29
4,070
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2016
Director of Finance/CFO 63 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/01/2016
Director/Board Member 60 01/01/2016
Director/Board Member 67 01/01/2016
Date Insider Type Main position Quantity % Market Cap.
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
+6.45%+3.12%-62.07%-76.26% 18.93M
+2.07%+13.76%+65.44%+106.53% 71.56B
-3.71%-4.82%+30.51%+58.91% 54.43B
-2.86%-6.36%-3.90%+450.50% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
-0.67%-2.51%-18.99%-15.03% 23.14B
+0.07%+0.90%+38.29%-20.43% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
-0.01%-6.17%+31.88%+135.87% 12.54B
Average -0.06%+3.05%+40.93%+168.49% 26.65B
Weighted average by Cap. -0.71%+3.63%+49.56%+158.43%

Financials

2024 2025
Net sales - -
Net income -1.32B -8.26M -7.16M -6.71M -6.12M -11.52M -789M -11.7M -79.06M -30.87M -395M -31.02M -30.35M -2.15B -13.5M -11.7M -10.97M -10M -18.82M -1.29B -19.13M -129M -50.44M -645M -50.69M -49.6M
Net Debt -3.58B -22.43M -19.44M -18.23M -16.62M -31.27M -2.14B -31.77M -215M -83.79M -1.07B -84.22M -82.39M -2.81B -17.64M -15.29M -14.34M -13.07M -24.6M -1.68B -24.99M -169M -65.91M -843M -66.24M -64.81M
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
14/08/26 ¥33.00 +6.45% 465,700
13/08/26 ¥31.00 -6.06% 339,400
12/08/26 ¥33.00 0.00% 867,200
10/08/26 ¥33.00 +3.12% 641,300
07/08/26 ¥32.00 -3.03% 1,036,800

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4883 Stock